<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122634">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811472</url>
  </required_header>
  <id_info>
    <org_study_id>CLCQ908A2216</org_study_id>
    <secondary_id>2013-000049-38</secondary_id>
    <nct_id>NCT01811472</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients</brief_title>
  <official_title>A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of core part of this study is to determine whether LCQ908 effectively lowers
      liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects
      with non-alcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in percentage of fat in the liver as assessed using MRI at Week 24</measure>
    <time_frame>From baseline to week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective of the study is to evaluate the efficacy of LCQ908 in reducing liver fat from baseline after 24 weeks of treatment in subjects with non-alcoholic fatty liver disease  (NAFLD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percentage of fat in the liver as assessed using MRI at Week 12</measure>
    <time_frame>From baseline to week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the changes in liver fat after 12 weeks of treatment in subjects with NAFLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders at 24</measure>
    <time_frame>From baseline to week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of responders will be calculated using the data collected at 24 weeks: a. A reduction of ≥ 30% from baseline in liver fat b. A reduction of ≥ 50% from baseline in liver fat c. Liver fat content &lt; 10% d. Liver fat content &lt; 5.6%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline values for alanine aminotransferase (ALT) , aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT)</measure>
    <time_frame>Baseline,  6, 12, and 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death as assessment of safety and tolerability</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the safety and tolerability in subjects with NAFLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting and post-prandial triglycerides</measure>
    <time_frame>Baseline, 6 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in waist circumference</measure>
    <time_frame>Baseline, 12 and 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with normalized liver enzymes (ALT and AST &lt;40 IU/L)</measure>
    <time_frame>Week 6, week 12 and week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCQ908 5mg/10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active study treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCQ908 10mg/20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active study treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCQ908</intervention_name>
    <description>LCQ908 5 mg, 10 mg, 20 mg tablets</description>
    <arm_group_label>LCQ908 5mg/10mg</arm_group_label>
    <arm_group_label>LCQ908 10mg/20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of liver steatosis during the preceding 24 months

          -  History of fasting TGs &gt; 200 mg/dL (confirmed at screening).

          -  Liver fat ≥ 10% as determined by the central MRI laboratory.

          -  Subjects on the following medications can be included if these medications are
             medically necessary, cannot be stopped and the investigator feels their dose will
             remain stable for the duration of the double-blind treatment period:

               1. Stable dose of anti-diabetic medications (metformin and/or sulfonylureas) for at
                  least 8 weeks prior to screening.

               2. Stable doses of beta-blockers and thiazide diuretics for at least 8 weeks prior
                  to screening.

               3. Stable doses of fibrates, statins, niacin, ezetimibe for at least 8 weeks prior
                  to screening.

               4. Stable dose of vitamin E in patients taking &gt;200 IU/day for at least 6 months
                  prior to screening.

        Exclusion Criteria:

          -  Treatment with omega-3-acid ethyl esters or omega-3-polyunsaturated fatty acid
             (PUFA)-containing supplements &gt; 200 mg per day within 8 weeks of screening.

          -  Treatment with antiretrovirals, tamoxifen, methotrexate, cyclophosphamide,
             isotretinoin, bile acid binding resins or  pharmacologic doses of oral
             glucocorticoids (≥10 mg of prednisone per day or equivalent) within 8 weeks of
             screening.

          -  ALT or AST &gt; 250 IU/L at the time of screening.

          -  History/current evidence of heavy alcohol use or alcoholism (&gt; 21 drinks per week in
             men and &gt; 14 drinks per week in women) over a 2-year period prior to screening.

          -  Presence of chronic liver disease, such as chronic hepatitis B and/or C, alcoholic
             liver disease, hemochromatosis, Wilson's disease, known cirrhosis.

          -  Platelet count &lt;150,000 at screening.

          -  BMI &gt;45 Kg/m2.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multi-center,</keyword>
  <keyword>randomized,</keyword>
  <keyword>double-blind,</keyword>
  <keyword>NAFLD,</keyword>
  <keyword>elevated triglycerides</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
